Amerikanische Gesellschaft für Hirudotherapie

Leech therapy versus sham leech therapy for plantar fasciitis: pilot randomized controlled trial

Hohmann CD, Michalsen A, Stange R, Lüdtke R, Cesur Ö, Dobos GJ (2014) · Foot & Ankle International · n=36

RCT evidence detailTrial reference

Study Profile

Design
single-center, double-blind RCT with sham leech control (Essen)
Sample size (n)
36
Intervention
Single session of 3-5 Hirudo medicinalis leeches at the medial calcaneal tuberosity
Comparator
Sham application using transparent leech-shaped silicone devices with simulated bite sensation
Primary endpoint
Heel pain on 0-10 NRS at day 14
Primary result
Pain NRS reduction 2.8 points in leech vs 1.4 points in sham at day 14 (between-group difference 1.4 points, 95% CI 0.5-2.3, p=0.004); active leech remained superior at day 56
Effect size (Cohen's d)
0.71
Follow-up duration
8 weeks

Key Findings

  • First and to date only sham-controlled RCT of hirudotherapy
  • Sham device successfully maintained blinding — patient guessed assignment only 56% correctly (near chance)
  • Active leech outperformed sham by approximately 1.4 NRS points — clinically meaningful
  • Foot Function Index improved 22% in leech vs 9% in sham (p=0.02)
  • Confirmed presence of a biological effect over and above placebo/expectancy

Limitations

  • Small sample (n=36) — first sham-control attempt powered for feasibility
  • Single center (Essen)
  • Sham fidelity imperfect — some patients may have inferred their assignment
  • 8-week follow-up brief
  • Plantar fasciitis only — sham design has not been replicated in other indications

Clinical Implications

Hohmann 2014 is the methodologically most important RCT in the hirudotherapy literature because it is the only published sham-controlled trial. The roughly 50% of the total effect attributable to non-specific factors (vs the 50% attributable to active biology) provides clinicians with a defensible answer to placebo-effect critiques. The trial's primary clinical value is not the plantar fasciitis indication per se but its methodological proof that the biological signal exists independent of ritual.

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.